Natural history models for lung Cancer: A scoping review

被引:0
作者
Nargund, Renu Sara [1 ]
Ishizawa, Sayaka [1 ]
Eghbalizarch, Maryam [1 ]
Yeh, Paul [2 ]
Saray, Seyyed Mostafa Mousavi Janbeh [1 ]
Nofal, Sara [1 ]
Geng, Yimin [3 ]
Cao, Pianpian [1 ,4 ]
Ostrin, Edwin J. [5 ]
Meza, Rafael [6 ,7 ]
Tammemagi, Martin C. [8 ]
Volk, Robert J. [1 ]
Lopez-Olivo, Maria A. [1 ]
Toumazis, Iakovos [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX USA
[2] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Management Policy & Community Hlth, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Res Med Lib, Houston, TX USA
[4] Purdue Univ, Dept Publ Hlth, W Lafayette, IN USA
[5] Univ Texas MD Anderson Canc Ctr, Gen Internal Med, Houston, TX USA
[6] British Columbia Canc Res Inst, Vancouver, BC, Canada
[7] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada
[8] Brock Univ, Dept Hlth Sci, St Catharines, ON, Canada
关键词
Simulation modeling; Lung cancer; Natural history; COST-EFFECTIVENESS; COMPUTED-TOMOGRAPHY; NEVER-SMOKERS; CURE THRESHOLD; BREAST-CANCER; RISK; MORTALITY; PROGRAM; IMPACT; PREVALENCE;
D O I
10.1016/j.lungcan.2025.108495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Natural history models (NHMs) of lung cancer (LC) simulate the disease's natural progression providing a baseline for assessing the impact of interventions. NHMs have been increasingly used to inform public health policies, highlighting their utility. The objective of this scoping review was to summarize existing LC NHMs, identify their limitations, and propose a framework for future NHM development. Methods: We searched MEDLINE, Embase, Web of Science, and IEEE Xplore from their inception to October 5, 2023, for peer-reviewed, full-length articles with an LC NHM. Model characteristics, their applications, data sources used, and limitations were extracted and narratively synthesized. Results: From 238 publications, 69 publications were included in our review, corresponding to 22 original LC NHMs and 47 model applications. The majority of the models (n = 15, 68 %) used a microsimulation approach. NHM parameters were predominately informed by cancer registries, trial and institutional data, and literature. Model quality and performance were evaluated in 8 (36 %) models. Twenty (91 %) models included at least one carcinogenesis risk factor-primarily age, sex, and smoking history. Three (14 %) LC NHMs modeled progression in never-smokers; one (5 %) addressed recurrence. Non-tobacco smoking, nodule type, and biomarker expression were not considered in existing NHMs. Based on our findings, we proposed a framework for future LC NHM development which incorporates recurrence, nodule type differentiation, biomarker expression levels, biological factors, and non-smoking-related risk factors. Conclusion: Regular updating and future research are warranted to address limitations in existing NHMs thereby ensuring relevance and accuracy of modeling approaches in the evolving LC landscape.
引用
收藏
页数:12
相关论文
共 121 条
  • [1] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [2] Cost-effectiveness of lung MRI in lung cancer screening
    Allen, Bradley D.
    Schiebler, Mark L.
    Sommer, Gregor
    Kauczor, Hans-Ulrich
    Biederer, Juergen
    Kruser, Timothy J.
    Carr, James C.
    Hazen, Gordon
    [J]. EUROPEAN RADIOLOGY, 2020, 30 (03) : 1738 - 1746
  • [3] Feasibility of lung cancer screening in resource-poor areas
    不详
    [J]. LANCET RESPIRATORY MEDICINE, 2022, 10 (04) : 313 - 313
  • [4] [Anonymous], Cancer intervention and surveillance modeling netwok: Cisnet model registry uwbcs (wisconsin)
  • [5] [Anonymous], Veritas Health Innovation
  • [6] [Anonymous], 2013, Clarviate
  • [7] [Anonymous], Median
  • [8] Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening
    Bastani, Mehrad
    Toumazis, Iakovos
    Hedou, Julien
    Leung, Ann
    Plevritis, Sylvia K.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2021, 18 (12) : 1614 - 1623
  • [9] Bethune Gillian, 2010, J Thorac Dis, V2, P48
  • [10] Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates
    Blom, Erik F.
    ten Haaf, Kevin
    de Koning, Harry J.
    [J]. LUNG CANCER, 2020, 139 : 200 - 206